Heart and iron deficiency anaemia in rats with renal insufficiency: The role of hepcidin

Nephrology

Volumn 13, Issue 7, 2008, Pages 636-645

  Toblli, Jorge Eduardo ^a   Cao, Gabriel ^a   Rivas, Carlos ^a   Kulaksiz, Hasan ^b  

^a HOSPITAL ALEMÁN   (Argentina)

^b UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Anaemia; Chronic renal disease; Heart failure; Inflammation; Iron

Indexed keywords

ANTIBODY; CASPASE 3; ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; HEPCIDIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 6; IRON; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; HEART WEIGHT; IMMUNOHISTOCHEMISTRY; INFLAMMATION; IRON DEFICIENCY ANEMIA; IRON METABOLISM; KIDNEY FAILURE; MALE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANEMIA, IRON-DEFICIENCY; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; CASPASE 3; ERYTHROPOIETIN; FERRITINS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; KIDNEY; MALE; MYOCARDIUM; RATS; RATS, SPRAGUE-DAWLEY; RENAL INSUFFICIENCY; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR FUNCTION, LEFT;

EID: 54049084164     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2008.01019.x     Document Type: Article

References (42)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am. J. Kidney Dis. 1998 32 (Suppl 3 S112 19.
2. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease. A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003 108 : 2154 69.
3. Levey AS, Beto JA, Coronado BE et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am. J. Kidney Dis. 1998 32 : 853 906.
4. Meyer KB, Levey AS. Controlling the epidemic of cardiovascular disease in chronic renal disease: Report from the National Kidney Foundation Task Force on Cardiovascular Disease. J. Am. Soc. Nephrol. 1998 9 (Suppl 12 S31 42.
5. Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end stage renal disease. Kidney Int. 1989 36 : 286 90.
6. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE. Outcome and risk factors for left ventricular disorders in chronic uremia. Nephrol. Dial. Transplant. 1996 11 : 1277 85.
7. London GM, Pannier B, Guerin AP et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: Follow-up of an interventional study. J. Am. Soc. Nephrol. 2001 12 : 2759 67.
8. Paoletti E, Cassottana P, Bellino D, Specchia C, Messa P, Cannella G. Left ventricular geometry and adverse cardiovascular events in chronic hemodialysis patients on prolonged therapy with ACE inhibitors. Am. J. Kidney Dis. 2002 40 : 728 36.
9. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J. Am. Coll. Cardiol. 2002 39 : 1780 6.
10. Anand I, McMurray JJ, Whitmore J et al. Anemia and its relationship to clinical outcome in heart failure. Circulation 2004 110 : 149 54.
11. Sharma R, Francis DP, Pitt B, Poole-Wilson PA, Coats AJ, Anker SD. Haemoglobin predicts survival in patients with chronic heart failure: A substudy of the ELITE II trial. Eur. Heart J. 2004 25 : 1021 8.
12. Silverberg DS, Wexler D, Iaina A. The role of anemia in the progression of congestive heart failure. Is there a place for erythropoietin and intravenous iron? J. Nephrol. 2004 17 : 749 61.
13. Felker GM, Gattis WA, Leimberger JD et al. Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. Am. J. Cardiol. 2003 92 : 625 8.
14. Kosiborod M, Smith GL, Radford MJ, Foody JM, Krumholz HM. The prognostic importance of anemia in patients with heart failure. Am. J. Med. 2003 114 : 112 19.
15. Szachniewicz J, Petruk-Kowalczyk J, Majda J et al. Anaemia is an independent predictor of poor outcome in patients with chronic heart failure. Int. J. Cardiol. 2003 90 : 303 8.
16. Opasich C, Cazzola M, Scelsi L et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur. Heart J. 2005 26 : 2232 7.
17. Brucks S, Little WC, Chao T et al. Relation of anemia to diastolic heart failure and the effect on outcome. Am. J. Cardiol. 2004 93 : 1055 7.
18. Anand IS, Kuskowski MA, Rector TS et al. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: Results from Val-HeFT. Circulation 2005 112 : 1121 7.
19. Macdougall IC. Could anti-inflammatory cytokine therapy improve poor treatment outcomes in dialysis patients? Nephrol. Dial. Transplant. 2004 19 (Suppl 5 V73 8.
20. Toblli JE, DeRosa G, Rivas C et al. Cardiovascular protective role of a low-dose antihypertensive combination in obese Zucker rats. J. Hypertens. 2003 21 : 611 20.
21. Zen Y, Fujii T, Itatsu K et al. Biliary cystic tumors with bile duct communication: A cystic variant of intraductal papillary neoplasm of the bile duct. Mod. Pathol. 2006 19 : 1243 54.
22. Ralph JA, Zocco D, Bresnihan B, Fitzgerald O, McEvoy AN, Murphy EP. A role for type 1α corticotropin-releasing hormone receptors in mediating local changes in chronically inflamed tissue. Am. J. Pathol. 2007 170 : 1121 33.
23. Kulaksiz H, Gehrke SG, Janetzko A et al. Pro-hepcidin expression and cell specific localization in the liver and its regulation in hereditary haemochromatosis, chronic renal insufficiency, and renal anaemia. Gut 2004 53 : 735 43.
24. Harrison-Findik DD, Schafer D, Klein E et al. Alcohol metabolism-mediated oxidative stress down-regulates hepcidin transcription and leads to increased duodenal iron transporter expression. J. Biol. Chem. 2006 281 : 22974 82.
25. Pietrangelo A, Caleffi A, Henrion J et al. Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes. Gastroenterology 2005 128 : 470 9.
26. Fein E, Merle U, Ehehalt R, Herrmann T, Kulaksiz H. Regulation of hepcidin in HepG2 and RINm5F cells. Peptides 2007 28 : 951 7.
27. Dong F, Zhang X, Culver B, Chew HG Jr., Kelley RO, Ren J. Dietary iron deficiency induces ventricular dilation, mitochondrial ultrastructural aberrations and cytochrome c release: Involvement of nitric oxide synthase and protein tyrosine nitration. Clin. Sci. 2005 109 : 277 86.
28. Koc M, Nad'ová Z, Kovár J. Sensitivity of cells to apoptosis induced by iron deprivation can be reversibly changed by iron availability. Cell Prolif. 2006 39 : 551 61.
29. Watanabe K, Yamashita Y, Ohgawara H et al. Iron content of rat serum ferritin. J. Vet. Med. Sci. 2001 63 : 587 9.
30. Ganz T. Molecular control of iron transport. J. Am. Soc. Nephrol. 2007 18 : 394 400.
31. Kulaksiz H, Theilig F, Bachmann S et al. The iron-regulatory peptide hormone hepcidin: Expression and cellular localization in the mammalian kidney. J. Endocrinol. 2005 184 : 361 70.
32. Merle U, Fein E, Gehrke SG, Stremmel W, Kulaksiz H. The iron regulatory peptide hepcidin is expressed in the heart and regulated by hypoxia and inflammation. Endocrinology 2007 148 : 2663 8.
33. Yeh KY, Yeh M, Glass J. Hepcidin regulation of ferroportin 1 expression in the liver and intestine of the rat. Am. J. Physiol. Gastrointest. Liver Physiol. 2004 286 : G385 94.
34. Ladoux A, Frelin C. Cardiac expressions of HIF-1 alpha and HLF/EPAS, two basic loop helix/PAS domain transcription factors involved in adaptative responses to hypoxic stresses. Biochem. Biophys. Res. Commun. 1997 240 : 552 6.
35. Stroka DM, Burkhardt T, Desbaillets I et al. HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB J. 2001 15 : 2445 53.
36. Jürgensen JS, Rosenberger C, Wiesener MS et al. Persistent induction of HIF-1alpha and -2alpha in cardiomyocytes and stromal cells of ischemic myocardium. FASEB J. 2004 18 : 1415 17.
37. Volm M, Koomägi R. Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer. Anticancer Res. 2000 20 : 1527 33.
38. Pagel H, Jelkmann W, Weiss C. A comparison of the effects of renal artery constriction and anemia on the production of erythropoietin. Pfluegers Arch. 1988 413 : 62 6.
39. Brines M, Cerami A. Discovering erythropoietin's extra-hematopoietic functions: Biology and clinical promise. Kidney Int. 2006 70 : 246 50.
40. Anagnostou A, Liu Z, Steiner M et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc. Natl. Acad. Sci. USA 1994 91 : 3974 8.
41. Wright GL, Hanlon P, Amin K, Steenbergen C, Murphy E, Arcasoy MO. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J. 2004 18 : 1031 3.
42. Jongen-Lavrencic M, Peeters HR, Rozemuller H et al. IL-6-induced anaemia in rats: Possible pathogenetic implications for anemia observed in chronic inflammations. Clin. Exp. Immunol. 1996 103 : 328 34.